Clinical features of cisplatin vestibulotoxicity and hearing loss.
Patients treated with cisplatin were observed in an otoneurological study with special reference to cochlear and vestibular toxicity. Toxicity-related symptoms appeared to be almost all transient. As with leukopenia, hearing loss and dizziness often occurred after several weeks of administration. In the equilibrium examinations, some abnormal findings such as spontaneous nystagmus and positional nystagmus were seen. Caloric tests and body sway tests detected abnormal findings in the early stages of cisplatin-related vestibulotoxicity.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002150:Caloric Tests; D002945:Cisplatin / Q000009:adverse effects*; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009759:Nystagmus, Pathologic / Q000139:chemically induced; D014012:Tinnitus / Q000139:chemically induced; D014722:Vestibule, Labyrinth / Q000187:drug effects*
D002945:Cisplatin